Amneal Pharmaceuticals (AMRX)
(Real Time Quote from BATS)
$8.17 USD
+0.21 (2.64%)
Updated Aug 5, 2025 12:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMRX 8.17 +0.21(2.64%)
Will AMRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMRX
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
AMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
Other News for AMRX
Amneal Pharmaceuticals (AMRX) Partners with Knight for CREXONT Distribution
Knight Therapeutics announces CREXONT regulatory submission in Mexico
Amneal Pharmaceuticals Inc Q2 2025 Earnings: EPS of $0. ...
Amneal Reports Second Quarter 2025 Financial Results | AMRX Stock News
Amneal Pharmaceuticals Non-GAAP EPS of $0.25 beats by $0.08, revenue of $725M misses by $19.56M